Strategic Focus Target opportunities in Type 1 Diabetes therapies and companion animal models (dogs and cats) where their encapsulated stem cell–based approach could complement or replace current insulin regimens, offering near-normal glycemic control and reduced device burden.

Exosome Platform Leverage engineered exosome capabilities for regenerative skin care and joint therapies to diversify partnerships with biotech, contract research organizations, and cosmetic/devices players seeking advanced, well-characterized extracellular vesicle products.

Translational Partnerships Capitalize on existing collaborations with scientific institutions and university validation to accelerate co-development, sponsored research, and milestone-driven deals that de-risk early-stage programs for potential acquirers or licensees.

Low-Volume Growth Position for early-stage, high-value collaborations rather than large-scale manufacturing deals given current revenue and funding levels; pursue grant-funded programs, milestone-driven partnerships, and advisory roles with larger biotechs aiming to augment portfolios.

Technology Stack Highlight capabilities in encapsulation tech, islet-like devices, and robust exosome isolation/purity assays to attract CROs, device developers, and pharma partners seeking validated platform technologies to de-risk product development.